A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

345

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

ALX-0061

OTHER

Placebo

DRUG

Methotrexate

Stable background dose of commercially available methotrexate (not provided by the Sponsor).

Trial Locations (94)

1000

Investigator Site 1, Skopje

Investigator Site 2, Skopje

1038

Investigator Site, Budapest

1070

Investigator Site, Brussels

1200

Investigator Site, Brussels

1233

Investigator Site, Sofia

1612

Investigator Site, Sofia

2025

Investigator Site, Chisinau

3800

Investigator Site, Szikszó

4000

Investigator Site, Liège

4001

Investigator Site, Plovdiv

5600

Investigator Site, Békéscsaba

5700

Investigator Site, Gyula

5800

Investigator Site, Pleven

6500

Investigator Site, Baja

7000

Investigator Site 1, Rousse

Investigator Site 2, Rousse

8000

Investigator Site, Székesfehérvar

8200

Investigator Site, Veszprém

8230

Investigator Site, Balatonfüred

9000

Investigator Site, Ghent

Investigator Site, Varna

10018

Investigator Site, New York

10117

Investigator Site, Berlin

11000

Investigator Site 1, Belgrade

Investigator Site 2, Belgrade

Investigator Site 3, Belgrade

11201

Investigator Site, Brooklyn

12850

Investigator Site, Prague

15702

Investigator Site, Santiago de Compostela

18205

Investigator Site, Niška Banja

20582

Investigator Site, Lublin

21112

Investigator Site, Novi Sad

22081

Investigator Site, Hamburg

25714

Investigator Site, Monclova

28007

Investigator Site, Madrid

28041

Investigator Site, Madrid

29406

Investigator Sie, Charleston

29572

Investigator Site, Myrtle Beach

30281

Investigator Site, Stockbridge

32804

Investigator Site, Orlando

33016

Investigator Sites, Hialeah

Investigator Site, Miami Lakes

33030

Investigator Site, Homestead

33135

Investigator Site, Miami

35216

Investigator Site, Birmingham

37000

Investigator Site, León

37007

Investigator Site, Salamanca

38119

Investigator Site, Memphis

40954

Investigator Site, Katowice

50973

Investigator Site, Cologne

60200

Investigator Site, Brno

60773

Investigator Site, Poznan

61231

Investigator Site, Bad Nauheim

64000

Investigator Site, Monterrey

64460

Investigator Site, Monterrey

66209

Investigator Site, Overland Park

71203

Investigator Site, Monroe

75150

Investigator Site, Mesquite

76001

Investigator Site, Zlín

77900

Investigator Site, Olomouc

80000

Investigator Site, Culiacán

81338

Investigator Site, Gdynia

82300

Investigator Site, Elblag

85168

Investigator Site, Bydgoszcz

87100

Investigator Site, Torun

87102

Investigator Site, Albuquerque

90017

Investigator Site, Los Angeles

90036

Investigator site, Los Angeles

90712

Investigator Site, La Palma

92543

Investigator Site, Hemet

93003

Investigator Site, Ventura

96500

Investigator Site, Sochaczew

97070

Investigator Site, Mérida

300057

Investigator Site, Timișoara

410028

Investigator Site, Oradea

540142

Investigator Site, Târgu Mureş

800578

Investigator Site, Brăila

01605

Investigator Site, Worcester

Unknown

Investigator Site, Prague

Investigator Site, Berlin

Investigator Site, Frankfurt

Investigator Site, Elblag

0102

Investigator Site, Tbilisi

0159

Investigator Site 1, Tbilisi

Investigator Site 2, Tbilisi

0160

Investigator Site, Tbilisi

0179

Investigator Site, Tbilisi

03100

Investigator Site 1, Mexico City

06700

Investigator Site 2, Mexico City

05825

Investigator Site, Grodzisk Mazowiecki

02653

Investigator Site, Warsaw

010976

Investigator Site, Bucharest

020475

Investigator Site, Bucharest

All Listed Sponsors
lead

Ablynx, a Sanofi company

INDUSTRY

NCT02309359 - A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter